Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628874 | 0.84 | TLR9 (0.37) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628757 | 0.81 | TLR8 (0.35) | TLR8TLR9TLR7 | |
| SCHEMBL23628808 | 0.81 | TLR8 (0.39) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628846 | 0.81 | TLR8 (0.36) | TLR8TLR9TLR7 | |
| SCHEMBL23628837 | 0.81 | USP2 (0.36) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628807 | 0.81 | USP2 (0.38) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628873 | 0.80 | TLR9 (0.41) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628840 | 0.80 | TLR8 (0.36) | TLR8TLR9TLR7JAK2JAK1 | |
| SCHEMBL23760676 | 0.80 | TLR8 (0.36) | TLR8TLR9TLR7ROCK2ROCK1 | |
| SCHEMBL23628798 | 0.80 | TLR8 (0.36) | TLR8TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3847165-A1 | NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, PADI1 | TLR8 1800/4885TLR9 308/4885TLR7 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.